NASDAQ:FGEN FibroGen (FGEN) Stock Forecast, Price & News $16.98 -0.80 (-4.50%) (As of 04:18 PM ET) Add Compare Share Share Today's Range$15.61▼$17.7350-Day Range$16.11▼$20.5952-Week Range$8.67▼$25.69Volume1.78 million shsAverage Volume953,210 shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$24.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability FibroGen MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside50.5% Upside$24.83 Price TargetShort InterestBearish6.40% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment-0.09Based on 20 Articles This WeekInsider TradingSelling Shares$1.47 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.83) to ($2.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector369th out of 986 stocksPharmaceutical Preparations Industry167th out of 480 stocks 3.3 Analyst's Opinion Consensus RatingFibroGen has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.83, FibroGen has a forecasted upside of 50.5% from its current price of $16.50.Amount of Analyst CoverageFibroGen has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.40% of the float of FibroGen has been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in FibroGen has recently increased by 16.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFibroGen does not currently pay a dividend.Dividend GrowthFibroGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFibroGen has received a 74.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for the autoimmune system", "Clinical research services for cancer", and "Clinical research services for deficiency diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for FibroGen is -0.84. Previous Next 1.1 News and Social Media Coverage News SentimentFibroGen has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for FibroGen this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, FibroGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,465,928.00 in company stock.Percentage Held by InsidersOnly 2.82% of the stock of FibroGen is held by insiders.Percentage Held by Institutions76.89% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for FibroGen are expected to grow in the coming year, from ($2.83) to ($2.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroGen is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroGen is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About FibroGen (NASDAQ:FGEN) StockFibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.Read More Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Email Address FGEN Stock News HeadlinesJune 8, 2023 | msn.comFibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8%June 7, 2023 | benzinga.comCheck Out What Whales Are Doing With FGENJune 9, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.June 7, 2023 | reuters.comFibroGen's neuromuscular disorder therapy fails late-stage studyJune 7, 2023 | msn.comFGEN Slides after DMD Candidate Fails In Phase 3 TrialJune 7, 2023 | finance.yahoo.comFibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main GoalJune 7, 2023 | finance.yahoo.comFibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't LostJune 7, 2023 | reuters.comFibroGen's neuromuscular disorder drug fails in late-stage studyJune 9, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.June 7, 2023 | finance.yahoo.comFibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular DystrophyJune 7, 2023 | americanbankingnews.comMark Eisner Sells 1,090 Shares of FibroGen, Inc. (NASDAQ:FGEN) StockJune 6, 2023 | finance.yahoo.comFibroGen to Present at Jefferies Global Healthcare ConferenceJune 5, 2023 | msn.comFibroGen: Several Pamrevlumab Data Releases Could Change Scope Of BiotechJune 5, 2023 | americanbankingnews.comFibroGen Target of Unusually Large Options Trading (NASDAQ:FGEN)June 3, 2023 | americanbankingnews.comFibroGen (NASDAQ:FGEN) Stock Rating Upgraded by Stifel NicolausJune 2, 2023 | msn.comFibroGen raised to buy by Stifel ahead of Phase 3 data for pamrevlumabJune 2, 2023 | benzinga.comLooking At FibroGen's Recent Unusual Options ActivityJune 2, 2023 | msn.comStifel Upgrades FibroGen (FGEN)May 31, 2023 | msn.comUnusual Put Option Trade in FibroGen (FGEN) Worth $701.96KMay 31, 2023 | benzinga.comFibroGen Unusual Options Activity For May 31May 23, 2023 | msn.comFibroGen's Return on Invested Capital OverviewMay 22, 2023 | benzinga.comFibroGen Unusual Options ActivityMay 18, 2023 | baystreet.caFibroGen Slips on Test ResultsMay 18, 2023 | msn.comFibroGen stock rises after roxadustat matches Sepo in Chinese trial for anemiaMay 18, 2023 | finance.yahoo.comFibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced AnemiaMay 17, 2023 | americanbankingnews.comAnalysts Set FibroGen, Inc. (NASDAQ:FGEN) PT at $23.40May 13, 2023 | americanbankingnews.comWilliam Blair Analysts Reduce Earnings Estimates for FibroGen, Inc. (NASDAQ:FGEN)See More Headlines FGEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FGEN Company Calendar Last Earnings5/08/2023Today6/09/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FGEN CUSIPN/A CIK921299 Webwww.fibrogen.com Phone(415) 978-1200Fax415-978-1902Employees566Year FoundedN/APrice Target and Rating Average Stock Price Forecast$24.83 High Stock Price Forecast$35.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+47.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-293,650,000.00 Net Margins-264.63% Pretax Margin-266.12% Return on Equity-879.75% Return on Assets-50.26% Debt Debt-to-Equity RatioN/A Current Ratio1.69 Quick Ratio1.52 Sales & Book Value Annual Sales$140.73 million Price / Sales11.65 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-840.00Miscellaneous Outstanding Shares97,580,000Free Float94,830,000Market Cap$1.64 billion OptionableOptionable Beta0.78 Key ExecutivesEnrique A. ConternoChief Executive Officer & DirectorJuan GrahamChief Financial Officer & Senior Vice PresidentElias KouchakjiSenior VP-Clinical Development & Drug SafetyMark EisnerChief Medical Officer & Executive Vice PresidentJohn HunterChief Scientific OfficerKey CompetitorsGeronNASDAQ:GERNBELLUS HealthNASDAQ:BLUPacira BioSciencesNASDAQ:PCRXRocket PharmaceuticalsNASDAQ:RCKTSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInsiders & InstitutionsMark EisnerSold 1,090 sharesTotal: $20,524.70 ($18.83/share)ProShare Advisors LLCSold 2,203 shares on 5/26/2023Ownership: 0.017%Putnam Investments LLCSold 20,215 shares on 5/22/2023Ownership: 0.098%Ameriprise Financial Inc.Sold 3,045 shares on 5/22/2023Ownership: 0.025%JPMorgan Chase & Co.Sold 11,762 shares on 5/18/2023Ownership: 0.172%View All Insider TransactionsView All Institutional Transactions FGEN Stock - Frequently Asked Questions Should I buy or sell FibroGen stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FGEN shares. View FGEN analyst ratings or view top-rated stocks. What is FibroGen's stock price forecast for 2023? 6 brokerages have issued 12 month price targets for FibroGen's stock. Their FGEN share price forecasts range from $14.00 to $35.00. On average, they predict the company's share price to reach $24.83 in the next year. This suggests a possible upside of 47.8% from the stock's current price. View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts. How have FGEN shares performed in 2023? FibroGen's stock was trading at $16.02 on January 1st, 2023. Since then, FGEN shares have increased by 4.9% and is now trading at $16.80. View the best growth stocks for 2023 here. Are investors shorting FibroGen? FibroGen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,690,000 shares, an increase of 16.8% from the April 30th total of 4,870,000 shares. Based on an average daily volume of 910,800 shares, the days-to-cover ratio is presently 6.2 days. Approximately 6.4% of the shares of the company are short sold. View FibroGen's Short Interest. When is FibroGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our FGEN earnings forecast. How were FibroGen's earnings last quarter? FibroGen, Inc. (NASDAQ:FGEN) released its quarterly earnings results on Monday, May, 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.05. The biopharmaceutical company had revenue of $36.16 million for the quarter, compared to the consensus estimate of $31.52 million. FibroGen had a negative trailing twelve-month return on equity of 879.75% and a negative net margin of 264.63%. FibroGen's revenue was down 40.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.68) earnings per share. What ETFs hold FibroGen's stock? ETFs with the largest weight of FibroGen (NASDAQ:FGEN) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Small Cap Growth AlphaDEX Fund (FYC). What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ). When did FibroGen IPO? (FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. What is FibroGen's stock symbol? FibroGen trades on the NASDAQ under the ticker symbol "FGEN." Who are FibroGen's major shareholders? FibroGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.56%), State Street Corp (4.18%), First Trust Advisors LP (2.79%), Baker BROS. Advisors LP (2.70%), Armistice Capital LLC (2.37%) and Geode Capital Management LLC (1.77%). Insiders that own company stock include Christine Chung, Enrique A Conterno, Juan Graham, K Peony Yu, Kalevi Kurkijarvi, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr. View institutional ownership trends. How do I buy shares of FibroGen? Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is FibroGen's stock price today? One share of FGEN stock can currently be purchased for approximately $16.80. How much money does FibroGen make? FibroGen (NASDAQ:FGEN) has a market capitalization of $1.64 billion and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis. How many employees does FibroGen have? The company employs 566 workers across the globe. How can I contact FibroGen? FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902. This page (NASDAQ:FGEN) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.